abbvie_0

AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T

pharmafile | January 8, 2019 | News story | Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t 

US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment of the company’s once much anticipated investigational cancer treatment Rova-T.

Having purchased the rights to Rova-T through its high profile acquisition of Stemcentrx, AbbVie announced in December that it would ‘stop enrolment’ into Phase 3 trials for the second-line therapy for advanced small-cell lung cancer.

The halting of clinical trials came after the data-monitoring committee found thatpatients taking Rova-T had worse survival rates than patients in the control arm.

Advertisement

The move came as a major setback for the American firm proving a major hindrance to AbbVie’s attempts to enter the lucrative solid tumour market.  The additional $4 billion write off comes in addition to the $5.8 billion paid for the acquisition of Stemcentrx in 2016.

AbbVie said in an SEC filing that “The estimated net impact of this impairment and the related adjustment to contingent consideration liabilities is approximately $4 billion.”

The company added that it “continues to evaluate information with respect to the Stemcentrx-related clinical development programs and will monitor the remaining $1 billion of intangible assets for further impairment.”

Louis Goss

Related Content

Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide

Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group in a …

Brenntag acquires mcePharma to expand GMP capabilities in biopharma services

Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …

Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly

Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and …

The Gateway to Local Adoption Series

Latest content